CY1120782T1 - Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα - Google Patents

Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα

Info

Publication number
CY1120782T1
CY1120782T1 CY181101090T CY181101090T CY1120782T1 CY 1120782 T1 CY1120782 T1 CY 1120782T1 CY 181101090 T CY181101090 T CY 181101090T CY 181101090 T CY181101090 T CY 181101090T CY 1120782 T1 CY1120782 T1 CY 1120782T1
Authority
CY
Cyprus
Prior art keywords
oxalate
prevention
compositions
treatment
related disease
Prior art date
Application number
CY181101090T
Other languages
English (en)
Inventor
Harmeet Sidhu
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35510266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120782(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of CY1120782T1 publication Critical patent/CY1120782T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μία φαρμακευτική σύνθεση που περιλαμβάνει ένα ή περισσότερα ένζυμα που αποικοδομούν οξαλικά, όπου το ένα ή περισσότερα ένζυμα είναι παγιδευμένα σε μία τρισδιάστατη δικτυωτή δομή κατασκευασμένη από πολυμερή που έχουν μεγέθη πόρων τα οποία επιτρέπουν τα υποστρώματα ενζύμου να διεισδύουν μέσω της δομής του δικτυωτού ώστε να φθάσουν στα ένζυμα.
CY181101090T 2004-06-15 2018-10-23 Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα CY1120782T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/868,242 US8486389B2 (en) 1997-05-23 2004-06-15 Compositions and methods for treating or preventing oxalate-related disease
PCT/US2005/021134 WO2005123116A2 (en) 2004-06-15 2005-06-15 Compositions and methods for treating or preventing oxalate-related disease
EP05786347.4A EP1771201B1 (en) 2004-06-15 2005-06-15 Compositions and methods for treating or preventing oxalate-related disease

Publications (1)

Publication Number Publication Date
CY1120782T1 true CY1120782T1 (el) 2019-12-11

Family

ID=35510266

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100853T CY1115745T1 (el) 2004-06-15 2014-10-16 Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY181101090T CY1120782T1 (el) 2004-06-15 2018-10-23 Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100853T CY1115745T1 (el) 2004-06-15 2014-10-16 Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου

Country Status (13)

Country Link
US (3) US8486389B2 (el)
EP (2) EP1771201B1 (el)
CN (2) CN101166421A (el)
CY (2) CY1115745T1 (el)
DK (2) DK1771201T3 (el)
ES (2) ES2692148T3 (el)
HK (2) HK1198922A1 (el)
LT (1) LT2803366T (el)
PL (2) PL1771201T3 (el)
PT (2) PT2803366T (el)
SI (2) SI1771201T1 (el)
TR (1) TR201815200T4 (el)
WO (1) WO2005123116A2 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
DE60226767D1 (de) * 2001-10-05 2008-07-03 Oxthera Inc Materialien und methoden zum reduzieren der konzentration von oxalat in fluiden
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
WO2005110469A2 (en) * 2004-05-07 2005-11-24 Oxthera, Inc. Methods and compositions for reducing oxalate concentrations
JP4938005B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
CA2610159C (en) 2005-06-10 2015-03-31 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
AU2005339139A1 (en) * 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2007075447A2 (en) * 2005-12-16 2007-07-05 Oxthera, Inc. Compositions and methods for oxalate reduction
ES2412254T3 (es) * 2006-08-02 2013-07-10 Altus Pharmaceuticals Inc. Oxalato-descarboxilasa cristalizada y métodos de uso
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
FR2936952A1 (fr) * 2008-10-09 2010-04-16 Monique Bellec Administration par voie orale de medicaments et complements nutritionnels
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
DK2270138T3 (en) 2009-07-02 2018-06-25 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate-degrading enzymes
IN2012DN00592A (el) * 2009-07-02 2015-06-12 Oxthera Intellectual Property Ab
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102725403A (zh) * 2009-11-25 2012-10-10 凯普托杰姆有限责任公司 草酸相关疾病治疗方法和组合物
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
US11077238B2 (en) 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
JOP20200118A1 (ar) * 2013-07-05 2017-06-16 Oxthera Intellectual Property Ab مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس
EP3277099B9 (en) 2015-04-02 2024-05-29 Oxidien Pharmaceuticals, Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
AU2017286220A1 (en) * 2016-06-13 2018-12-06 Oxthera Intellectual Property Ab Compositions and methods for the treatment or prevention of oxalate-related disorders
EP3554518A4 (en) 2016-12-15 2020-07-29 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS FOR MODULATING THE GROWTH OF A GENETICALLY MODIFIED INTESTINAL BACTERIAL CELL
WO2020018799A1 (en) 2018-07-18 2020-01-23 The University Of Chicago Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) * 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4888182A (en) 1983-04-11 1989-12-19 Board Of Regents Of The University Of Texas System Compositions and methods of treating calcium renal stones
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) * 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5279827A (en) 1991-01-16 1994-01-18 Allegheny-Singer Research Institute Extract and pharmaceutical composition for treatment of calcium oxalate stone disease and viral infections
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
UA34467C2 (uk) * 1992-11-30 2001-03-15 Зенека Лімітед Виділений та очищений днк фрагмент, що кодує оксалат-декарбоксилазу
EP1123660A3 (en) * 1993-04-16 2004-01-07 McCORMICK & COMPANY, INC. Encapsulation compositions
US5554147A (en) * 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
DE69428054T2 (de) 1994-05-18 2002-06-06 Human Genome Sciences, Inc. HUMANE OXALYL-CoA DECARBOXYLASE
US5604111A (en) * 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US6214980B1 (en) * 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US6033719A (en) * 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
JP4996780B2 (ja) * 1997-05-23 2012-08-08 オクセラ インコーポレイテッド シュウ酸塩関連疾患を予防するためのシュウ酸塩分解微生物またはシュウ酸塩分解酵素
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US20040120941A1 (en) 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
US6080404A (en) * 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US6566407B2 (en) * 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
AR020729A1 (es) 1998-10-09 2002-05-29 Gen Mills Marketing Inc Un metodo para el encapsulado de componentes sensibles en una matriz para obtener particulas discretas y estables durante su almacenamiento
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
RU2250764C2 (ru) 1999-06-07 2005-04-27 Наносфер, Инк. Способ нанесения покрытий на частицы и частицы, полученные этим способом
DE10026541A1 (de) 2000-05-27 2001-11-29 Zeiss Carl Vorrichtung zur präzisen Positionierung eines Bauteils, insbesondere eines optischen Bauteiles
DE60226767D1 (de) * 2001-10-05 2008-07-03 Oxthera Inc Materialien und methoden zum reduzieren der konzentration von oxalat in fluiden
US7407668B2 (en) * 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
AU2003274918A1 (en) 2002-08-20 2004-03-11 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
US6929940B1 (en) * 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
WO2005110469A2 (en) 2004-05-07 2005-11-24 Oxthera, Inc. Methods and compositions for reducing oxalate concentrations
AU2005339139A1 (en) * 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2007075447A2 (en) 2005-12-16 2007-07-05 Oxthera, Inc. Compositions and methods for oxalate reduction
ES2412254T3 (es) 2006-08-02 2013-07-10 Altus Pharmaceuticals Inc. Oxalato-descarboxilasa cristalizada y métodos de uso
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
EP1771201B1 (en) 2014-08-13
EP2803366A2 (en) 2014-11-19
ES2692148T3 (es) 2018-11-30
US20190091268A1 (en) 2019-03-28
PT1771201E (pt) 2014-11-06
HK1198922A1 (en) 2015-06-19
US20040234514A1 (en) 2004-11-25
WO2005123116A2 (en) 2005-12-29
LT2803366T (lt) 2018-12-27
CN104998253A (zh) 2015-10-28
DK1771201T3 (da) 2014-11-03
DK2803366T3 (en) 2018-11-05
US8486389B2 (en) 2013-07-16
TR201815200T4 (tr) 2018-11-21
US10149866B2 (en) 2018-12-11
PL1771201T3 (pl) 2015-01-30
SI1771201T1 (sl) 2014-12-31
US10653726B2 (en) 2020-05-19
EP2803366B1 (en) 2018-08-01
WO2005123116A3 (en) 2008-01-03
EP2803366A3 (en) 2015-02-18
EP1771201A4 (en) 2011-01-19
CY1115745T1 (el) 2017-01-25
HK1216080A1 (zh) 2016-10-14
PL2803366T3 (pl) 2018-12-31
SI2803366T1 (sl) 2018-12-31
US20140030324A1 (en) 2014-01-30
EP1771201A2 (en) 2007-04-11
CN101166421A (zh) 2008-04-23
ES2522898T3 (es) 2014-11-19
PT2803366T (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
CY1120782T1 (el) Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα
WO2006081079A8 (en) Crosslinkable hydrophilic materials from polymers having pendent michael donor groups
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
ATE528989T1 (de) Kristalline feste rasagilin-base
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1113160T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CY1115526T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
WO2007042554A3 (en) Methods and compositions for treating immune disorders
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
NO20081479L (no) 7-(2-Amino-1-hydroksyetyl)-4-hydroksybenzotiazol-2(3H)-ondenvater som beta2-adrenoceptoragonister
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
ECSP088759A (es) Composiciones farmacéuticas
CR11031A (es) Composiciones de enzima digestiva estable
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
EA200700225A1 (ru) Аналоги тетрапептида
EA200601608A1 (ru) Способ производства твёрдой фармацевтической композиции
WO2006069719A3 (en) Lyophilization of virosomes
DK1871391T3 (da) Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
CY1112980T1 (el) Φαρμακευτικες συνθεσεις, οι οποιες διαθετουν βελτιωμενα προφιλ διαλυσης για δυσδιαλυτες δραστικες ουσιες
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы